Company profile: hC Bioscience
1.1 - Company Overview
Company description
- Provider of engineered tRNA-based protein editing platforms and therapeutics, including PTCX (Patch) to suppress nonsense mutations in mRNA and restore full-length protein, SWTX (Switch) to mark disease-causing proteins for destruction, and engineered tRNA therapies to correct multiple mutant proteins across various disease indications.
Products and services
- Engineered tRNA Therapeutics: Context-agnostic therapies engineered from tRNAs that correct multiple mutant proteins across various disease indications by editing at the mRNA level
- PTCX (Patch): Platform-based system using engineered tRNAs to recognize and suppress nonsense mutations in mRNA transcripts, restoring truncated proteins to full length and functional integrity
- SWTX (Switch): Disease-targeted platform that marks unwanted, disease-causing proteins for destruction, enabling selective elimination of pathological proteins implicated in disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to hC Bioscience
Algeta
HQ: Norway
Website
- Description: Provider of targeted oncology therapies based on an alpha-pharmaceutical platform, including radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algeta company profile →
GeminX Pharmaceuticals
HQ: Canada
Website
- Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
Photocure
HQ: United States
Website
- Description: Provider of photodynamic specialty pharmaceuticals, including Hexvix/Cysview to improve bladder tumor detection and resection via Blue Light Cystoscopy, and Cevira, a photodynamic drug-device for non-surgical treatment of cervical HSIL; also supports patient registries and real-world evidence in bladder cancer. Norwegian-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Photocure company profile →
DiaCarta
HQ: United States
Website
- Description: Provider of precision molecular diagnostics, including CE/IVD-marked KRAS detection, for cancer screening, monitoring, and therapy guidance. Offerings include RadTox for real-time cfDNA treatment response; ColoScape for colorectal screening and FIT-positive triage via plasma cfDNA changes; QClamp for sensitive ctDNA mutation detection; OptiSeq Colorectal Cancer NGS Panel for actionable mutations; Oncuria urine biomarkers; and custom mini-MRD panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaCarta company profile →
ImmunoMet Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer patients, including Lixumistat (IM156), an orally bioavailable small molecule inhibitor of Protein Complex 1 that targets Oxidative Phosphorylation to reduce aberrant cell growth in cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoMet Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for hC Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to hC Bioscience
2.2 - Growth funds investing in similar companies to hC Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for hC Bioscience
4.2 - Public trading comparable groups for hC Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →